Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Glucagon; related peptides
Reexamination Certificate
2005-12-23
2010-06-15
Tsang, Cecilia (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Glucagon; related peptides
C530S300000, C514S012200, C424S001690
Reexamination Certificate
active
07737251
ABSTRACT:
This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.
REFERENCES:
patent: 4462941 (1984-07-01), Lee et al.
patent: 5424286 (1995-06-01), Eng
patent: 5493007 (1996-02-01), Burnier et al.
patent: 5580853 (1996-12-01), Sytkowski
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5789379 (1998-08-01), Drucker et al.
patent: 5834428 (1998-11-01), Drucker
patent: 5840733 (1998-11-01), Krantz et al.
patent: 5843440 (1998-12-01), Pouletty et al.
patent: 5942620 (1999-08-01), Krantz et al.
patent: 5952301 (1999-09-01), Drucker
patent: 5990077 (1999-11-01), Drucker
patent: 5994500 (1999-11-01), Drucker et al.
patent: 6051557 (2000-04-01), Drucker
patent: 6087375 (2000-07-01), Bridon et al.
patent: 6103233 (2000-08-01), Pouletty et al.
patent: 6107489 (2000-08-01), Krantz et al.
patent: 6184201 (2001-02-01), Drucker et al.
patent: 6277583 (2001-08-01), Krantz et al.
patent: 6277863 (2001-08-01), Krantz et al.
patent: 6284725 (2001-09-01), Coolidge et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6403324 (2002-06-01), Krantz et al.
patent: 6437092 (2002-08-01), Ezrin et al.
patent: 6440417 (2002-08-01), Thibaudeau et al.
patent: 6451974 (2002-09-01), Hansen
patent: 6500918 (2002-12-01), Ezrin et al.
patent: 6514500 (2003-02-01), Bridon et al.
patent: 6593295 (2003-07-01), Bridon et al.
patent: 6602981 (2003-08-01), Ezrin et al.
patent: 6610825 (2003-08-01), Ezrin et al.
patent: 6706892 (2004-03-01), Ezrin et al.
patent: 6723530 (2004-04-01), Drucker
patent: 6767887 (2004-07-01), Hoffmann et al.
patent: 6821949 (2004-11-01), Bridon et al.
patent: 6849714 (2005-02-01), Bridon et al.
patent: 6887470 (2005-05-01), Bridon et al.
patent: 6887849 (2005-05-01), Bridon et al.
patent: 7090851 (2006-08-01), Bridon et al.
patent: 7112567 (2006-09-01), Bridon et al.
patent: 7144854 (2006-12-01), Bridon et al.
patent: 7166695 (2007-01-01), Krantz et al.
patent: 7226990 (2007-06-01), Knudsen et al.
patent: 7256253 (2007-08-01), Bridon et al.
patent: 7268113 (2007-09-01), Bridon et al.
patent: 7307148 (2007-12-01), Bousquet Gagnon et al.
patent: 2001/0047084 (2001-11-01), Knudsen et al.
patent: 2003/0170250 (2003-09-01), Ezrin et al.
patent: 2004/0127398 (2004-07-01), Bridon et al.
patent: 2004/0138100 (2004-07-01), Bridon et al.
patent: 2004/0156859 (2004-08-01), Ezrin et al.
patent: 2004/0266673 (2004-12-01), Bakis et al.
patent: 2005/0065075 (2005-03-01), Erickson et al.
patent: 2005/0070475 (2005-03-01), Bridon et al.
patent: 2005/0176641 (2005-08-01), Bakis et al.
patent: 2005/0176643 (2005-08-01), Bridon et al.
patent: 2006/0058235 (2006-03-01), Bridon et al.
patent: 2006/0135426 (2006-06-01), Bridon et al.
patent: 2006/0135428 (2006-06-01), Bridon et al.
patent: 2006/0241019 (2006-10-01), Bridon et al.
patent: 2007/0207958 (2007-09-01), Bridon et al.
patent: 2007/0269863 (2007-11-01), Bridon et al.
patent: 41 22 210 (1993-01-01), None
patent: 0602290 (1994-06-01), None
patent: WO-91/08220 (1991-06-01), None
patent: WO-93/25217 (1993-12-01), None
patent: WO-95/10302 (1995-04-01), None
patent: WO-96/06626 (1996-03-01), None
patent: WO 97/25074 (1997-01-01), None
patent: WO 97/29372 (1997-01-01), None
patent: WO 97/46584 (1997-12-01), None
patent: WO 98/00171 (1998-01-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO-98/08872 (1998-02-01), None
patent: WO 98/11437 (1998-03-01), None
patent: WO 98/24813 (1998-06-01), None
patent: WO-98/24813 (1998-06-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 99/24071 (1999-05-01), None
patent: WO-99/24075 (1999-05-01), None
patent: WO 99/24076 (1999-05-01), None
patent: WO-99/24462 (1999-05-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 99/43361 (1999-09-01), None
patent: WO 99/46283 (1999-09-01), None
patent: WO-99/48536 (1999-09-01), None
patent: WO 00/69902 (2000-05-01), None
patent: WO 00/70665 (2000-09-01), None
patent: WO-00/69900 (2000-11-01), None
patent: WO-00/69911 (2000-11-01), None
patent: WO-00/76550 (2000-12-01), None
patent: WO-0076551 (2000-12-01), None
patent: WO 01/17568 (2001-03-01), None
patent: WO 01/17614 (2001-03-01), None
patent: WO-01/68142 (2001-09-01), None
patent: WO 02/62844 (2002-01-01), None
patent: WO 02/66511 (2002-02-01), None
patent: WO 02/96935 (2002-05-01), None
patent: WO 2004/011498 (2004-02-01), None
patent: WO 2005/012346 (2005-02-01), None
patent: WO 2005/103087 (2005-04-01), None
patent: WO 2005/108418 (2005-06-01), None
patent: WO 2007/053946 (2007-05-01), None
patent: WO 2007/071068 (2007-06-01), None
Tavares et al., 2000, “Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon- like peptide-2 in rats,” American Journal of Physiology, Endocrinology and Metabolism, 278(1), pp. E134-E139.
Akii et al., 1984, “Endogenous opioids: biology and function,” Ann. Rev. Neurosci., vol. 7, pp. 223-255.
Stehle et al., 1997, “The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats,” Anti-cancer Drugs, vol. 8, pp. 677-685.
DaCambra et al., 2000, “Structural determinants for activity of glucagon-like peptide-2,” Biochemistry, vol. 39(30), pp. 8888-8894.
Oren and Shai, 1998, “Mode of action of linear amphipathic alpha-helical antimicrobial peptides,” Biopolymers (Peptide Science), vol. 47, pp. 451-463.
Patrias et al., 1994/1995,“Trimethylaminuria (Fish-malador syndrome) fnad the flavin monooxygenases”, Biotech Report, pp. 106-107.
Hirai et al., 1979, “A new mast cell degranulating peptide “mastoparan” in the venom ofVespula lewisii,” Chem. Pharm. Bull., vol. 27(8), pp. 1942-1944.
Reubic et al., 1982, “Specific high affinity binding sites for somatostatin-28 on pancreatic beta-cells: differences with brain somatostatin receptors,” Endocrinology, vol. 110(3), pp. 1049-1051.
Drucker, 2001, “Minireview: the glucagon-like peptides,” Endocrinology, vol. 142(2), pp. 521-527.
Thim et al., 1998, “Cart, a new anorectic peptide,” Int. J. Biochem. Cell. Biol., vol. 20, pp. 1281-1284.
Kapas et al., 1995, “Cloning and expression of cDNA endocing a rat adrenomedullin receptor,” J. Biol. Chem., vol. 270(43), pp. 25344-25347.
Smith et al., 1989, “Atrial natriuretic factor during fetal and postnatal life: a review,” J. Dev. Physiol., vol. 12, pp. 55-62.
Drucker et al., 1997, “Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV,” Nature Biotechnology, Nature Publishing, vol. 15(7), pp. 673-677.
Drucker et al., 1996, “Induction of intestinal epithelial proliferation by glucagon-like peptide 2,” Proc. Natl. Acad. Sci., vol. 93(15), pp. 7911-7916.
Proceedings of the 8thAmerican Peptide Symposium, 1983, 409-412.
Mumby et al., 1986, “Antisera of designed specificity for subunits of guanine nucleotide-binding regulatory proteins,” Proc. Natl., Acad. Sci., vol. 83, pp. 265-269.
Lovshin and Drucker, 2000, “New frontiers in the biology of GLP-2,” Regulatory Peptides, vol. 90(1-3), 27-32.
Selkoe, 1993, “Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease,” Tins, vol. 16, pp. 403-409.
Baksheeva and Fuller, 2000, “Humoral factors in intestinal adaptation,” Trends in Endocrinology and Metabolism, 2000, 11(10), 401-405.
Davis et al., 1991, “Reductionof Immunogenicity and extension of circulating half-life of peptides and proteins,” Peptide and Protein Drug Delivery, Marcel Dekker, Inc., NY, NY, 831-864.
Paige et al., 1995, “Prolonged circulation of recombin
Boudjellab Nissab
Bridon Dominique P.
Carette Julie
Leger Roger
Robitaille Martin
Audet Maury
ConjuChem Biotechnologies Inc.
Jones Day
Tsang Cecilia
LandOfFree
Long lasting glucagon-like peptide 2 (GLP-2) for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Long lasting glucagon-like peptide 2 (GLP-2) for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long lasting glucagon-like peptide 2 (GLP-2) for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4191896